In 2023 our SchurSign® product will be available to women in the US diagnosed with suspicious lesions in their breast. Because of SchurSign®‘s unique biomaterial characteristics, doctors will be able to provide their patients with less invasive, much more gentle, and equally successful treatment.
Breast cancer is big and growing due to higher life expectancy, systematic diagnostic and screening, but also due to environmental effects in younger women.
The earlier it is found, the better the chance for a non-radical therapy, such as total breast amputation.
Non-radical or minimally invasive therapies require better ultrasound visibility of markers. Current markers are a provisional solution at best.
Current markers are a provisional solution at best.
That’s why women and their doctors need SchurSign®.
– a sure sign!